Figure 1: Top 10 Selling Products of Amgen (US$ mill)

Source: GlobalData, Pharma Intelligence Center, [Accessed 19th Dec 2017]

Figure 1 displays the sales values of the top ten products of Amgen for 2016. Enbrel and Neulasta are the best performing drugs by a large margin; however, many of their other drugs are also top performers. There top 7 drugs all make over 1,000 (US$m). Going forward Enbrel and Neulasta revenues are expected to half by 2023 meaning Amgen position may not be as strong going forward, but Amgen are expecting another high performing drug in Repatha; expected to be valued at 3,440 (US$m) by 2023.